Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

Janjigian, Yelena Y., Al-Batran, Salah-Eddin, Wainberg, Zev A., Van Cutsem, Eric, Molena, Daniela, Muro, Kei, Hyung, Woo Jin, Wyrwicz, Lucjan S., Oh, Do-Youn, Omori, Takeshi, Moehler, Markus, Garrido, Marcelo, Oliveira, Sulene C. S., Liberman, Moishe, Castro Oliden, Victor, Bilici, Mehmet, Kurland, John F., Xynos, Ioannis, Mann, Helen, Tabernero, Josep